<div id="readability-page-1"><p>In a report released today, Roger Song from Jefferies maintained a Buy rating on Cabaletta Bio, with a price target of <span id="expert-recommendation-target">$14.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Cabaletta Bio, and Oruka Therapeutics. According to TipRanks, Song has an average return of <span>-5.1%</span> and a 37.50% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $17.83.</p></div>

CABA

<p>Jefferies analyst Roger Song maintains a Buy rating for Cabaletta Bio with a $14.00 price target. The analyst consensus is a Strong Buy with an average price target of $17.83. Song, who covers the Healthcare sector, has an average return of -5.1% and a 37.50% success rate on recommended stocks.</p>

Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)